Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mufemilast Phase 3 in Moderate to Severe Plaque Psoriasis
NCT04839328Phase 3Completed
- Sponsor
- Tianjin Hemay Biotech
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mufemilast in plaque psoriasis, sponsored by Tianjin Hemay Biotech. Started Jan 2022; status: completed.
02
Drugs
mufemilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04839328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839328.